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 CRH test: CRH-stimulated peak cortisol  6 600 nmol/l predict-
ed early failure in 78% (NPV 100%). All relapses recorded 
CRH-stimulated peak cortisol  6 485 nmol/l.  Metyrapone test: 
11-deoxycortisol  6 345 nmol/l predicted an early failure in 
86% of cases (NPV 94%).  Conclusion: Predictive factors of 
surgical failure are morning cortisol  6 200 nmol/l, 11-deoxy-
cortisol  6 345 nmol/l after metyrapone and CRH-stimulated 
cortisol  6 600 nmol/l. CRH and/or metyrapone testing are 
not superior to morning cortisol concentration in the predic-
tion of outcome of TS. Careful long-term follow-up remains 
necessary independent of the outcome of biochemical 
 testing.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Cushing’s disease (CD) is caused by adrenocorticotro-
pin (ACTH)-secreting pituitary tumors. Transsphenoi-
dal surgery (TS) is the first choice of treatment for CD. 
Although being a safe treatment, with a reported 30-day 
mortality in experienced hands of less than 1%, surgical 
cure is not achieved in all patients  [1–3] . The reported 
initial success rate for pituitary surgery for CD varies be-
tween 60 and 86%, however the true rate tends to be low-
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 Abstract 
 Objective: Transsphenoidal surgery (TS) is the primary ther-
apy for Cushing’s disease (CD). The aims of this retrospective 
study were twofold: (i) investigate early and late results of
TS for CD, and (ii) evaluate various postoperative tests in or-
der to predict the outcome of TS.  Methods: We reviewed
the long-term outcome in 79 patients with CD who under-
went TS (median follow-up 84 months, range 6–197). Within 
2 weeks after surgery, morning serum cortisol concentra-
tions were obtained (n = 78) and corticotropin-releasing hor-
mone (CRH) (n = 53) and metyrapone tests (n = 72) were per-
formed. Three groups of outcome were identified: sustained 
remission, early failure (persistent CD), and late relapse.  Re-
sults: Immediate postoperative remission was achieved in 
51 patients (65%), whereas 28 patients (35%) had persistent 
CD after TS. Ten patients developed recurrent CD after initial 
remission (20%).  Morning cortisol: all relapses but one record-
ed serum cortisol  1 50 nmol/l. A cortisol threshold value of 
200 nmol/l has a positive predictive value of 79% for imme-
diate surgical failure (negative predictive failure [NPV] 97%). 
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er since up to 25% of patients suffer from recurrence after 
apparent remission  [4–12] . Moreover, success and recur-
rence rates per center largely depend on biochemical cri-
teria which can differ per center. Immediately after suc-
cessful resection of the autonomous corticotropic adeno-
ma, the remaining corticotropic cells are still suppressed 
in the majority of patients. Therefore, low or undetectable 
postoperative serum cortisol levels are associated with 
long-term remission  [1, 6, 12–16] . Inability to increase the 
secretion of ACTH (and subsequently 11-deoxycortisol 
secretion) after administration of metyrapone, an 11  -
hydroxylase (CYP11B1) blocker, may also indicate com-
plete surgical excision of the pituitary adenoma  [17] . Since 
corticotropic pituitary adenomas are generally suscepti-
ble to stimulation by corticotropin-releasing hormone 
(CRH), responsiveness to CRH in the early postoperative 
phase may reflect incomplete resection of adenoma and 
an increased risk of recurrence  [6, 7, 18–21] .
 The objective of this survey was twofold: (i) to investi-
gate the early and late results of pituitary surgery for CD, 
and (ii) to compare the predictive values of three early 
postoperative tests (morning serum cortisol concentra-
tion, CRH test, and metyrapone test) in the individual 
assessment of outcome defined by 24-hour urinary free 
cortisol (UFC) excretion and 1 mg overnight dexametha-
sone testing at 12 weeks after pituitary surgery.
 Patients and Methods 
 Patients 
 Seventy-nine consecutive patients underwent primary pitu-
itary surgery for CD at the Erasmus Medical Centre Rotterdam 
between 1991 and 2006. We reviewed our data retrospectively. 
The study was approved as an institutional case-note review. The 
mean age of patients at the time of surgery was 40.8 years (SE 
1.46). The median follow-up period was 84 months (range 7–121). 
Sixty-three patients were female (80%). Clinical characteristics of 
patients are detailed in  table 1 .
 All patients were diagnosed preoperatively with CD according 
to the following criteria: clinical features, elevated excretion of 
free cortisol in 24-hour urine samples on at least two occasions, 
insufficient suppression of serum cortisol after 1 mg overnight 
dexamethasone (cutoff 50 nmol/l), loss of normal circadian 
rhythm of cortisol secretion and non-suppressed plasma ACTH 
levels in the presence of normal or elevated serum cortisol levels. 
Radiological imaging of the pituitary was performed by magnet-
ic resonance imaging (MRI). Macroadenoma was defined as a pi-
tuitary tumor with a diameter of  1 1 cm in any dimension on ra-
diological imaging  [22] . Pituitary adenomas not visible on preop-
erative MRI or adenomas  ! 1 cm in diameter were classified as 
microadenomas. The study population consisted of 21 patients 
with macroadenomas and 58 patients with microadenomas. 
Fourteen microadenomas could not be visualized preoperatively 
by MRI. Bilateral inferior petrosal sinus sampling (BIPSS) was 
performed if the size of the adenoma was  ! 6 mm, or if no adeno-
ma was present on radiological imaging. Basal bilateral petrosal 
sinus-to-peripheral plasma ACTH ratio of  1 2.0 or post-CRH 
stimulation ratio  6 3.0 were used to demonstrate pituitary ACTH 
hypersecretion  [23] .
 Presurgical treatment with adrenal enzyme inhibitors, such as 
ketoconazole (n = 59) and metyrapone (n = 1), was given during 
3 months until 1 day before pituitary surgery. Four different neu-
rosurgeons operated on the patients in our series. A transsphenoi-
dal selective adenomectomy was performed when the tumor was 
radiologically identified or, in cases of negative sellar imaging, 
hemihypophysectomy was performed on the side with ACTH lat-
Table 1. Patient characteristics of 79 patients with Cushing’s dis-
ease
Sustained
remission
(n = 41)
Early
failure
(n = 28)
Late
relapse
(n = 10)
Mean age in years (SE) 42.382.0 39.982.5 38.384.0
Sex
Male 11 4 1
Female 30 24 9
Mean follow-up months (SE) 75.987.2 91.9810.2 120.9819.8
Deaths 4 3 1
Lost to follow-up 4 1 1
Adenoma on MRI
Macroadenoma 7 12 2
Microadenoma 34 16 8
Visible 27 10 7
Non-visible 7 6 1
BIPSS 17 12 3
Pretreatment
Ketoconazole 31 23 5
Metyrapone 0 1 0
Postoperative pituitary insufficiency
No hormonal deficiency 31 19 7
1 axis 4 4 2
2 axes 3 4 1
3 or more axes 3 1 0
Morning cortisol (n = 78) 40 28 10
≤50 nmol/l 18 0 1
50–200 nmol/l 15 1 5
>200 nmol/l 7 27 4
Metyrapone test (n = 72) 37 27 8
11-deox <50 nmol/l 18 0 2
11-deox 50–150 nmol/l 8 0 1
11-deox 150–350 nmol/l 7 3 3
11-deox >350 nmol/l 4 24 2
CRH test (n = 53) 32 18 3
Max. cortisol ≤600 nmol/l 27 0 2
Max. cortisol >600 nmol/l 5 18 1
Max. ACTH ≤10 pmol/l 22 3 0
Max. ACTH >10 pmol/l 2 9 2
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eralization during BIPSS. On the day of surgery the patients re-
ceived 200 mg of hydrocortisone, which was tapered off to no dose 
within 4 days. In 1 patient, hydrocortisone could not be tapered 
postoperatively due to severe glucocorticoid withdrawal symp-
toms, such as fatigue, nausea and hypotension. All patients re-
ceived antibiotic prophylaxis (amoxicillin) in the perioperative 
period  [24, 25] .
 Postoperative Assessment 
 Between days 7 and 10 postoperatively, morning serum corti-
sol (n = 78) was measured at 08: 00 h, 72 h after the last dose of 
hydrocortisone. Subsequently, a metyrapone test (n = 72) and, 
from 1998 onwards, a CRH test (n = 53) were performed in the 
following days. Human CRH (Ferring BV, Hoofddorp, The Neth-
erlands) was used during the CRH test. At 07: 00 h, an indwelling 
forearm cannula was inserted and 30 min later 1   g/kg CRH was 
administered intravenously. Serum cortisol was measured at 15-
min intervals for 2 h. Plasma ACTH was also measured in 38 pa-
tients at 15-min intervals for 2 h. During the CRH test, patients 
were restricted to bed rest. The metyrapone stimulation test was 
performed after an overnight fast. The metyrapone stimulation 
test is routinely performed in our hospital after pituitary surgery 
in order to test the ACTH reserve. Following the measurement of 
morning serum cortisol, patients received 6 oral doses of 750 mg 
metyrapone (Alliance Pharmaceuticals Ltd, Chippenham, Wilts., 
UK) at 4-hour intervals. On the second day of the test, a fasting 
blood sample was taken for determination of 11-deoxycortisol, 
4 h after the last metyrapone dose  [17] . Pending the results of the 
postoperative tests, patients were discharged on hydrocortisone 
replacement therapy (40 mg/day). Patients who recorded 11-de-
oxycortisol levels  ! 350 nmol/l in the metyrapone test were con-
sidered to have secondary adrenal insufficiency and continued 
hydrocortisone replacement therapy until further notice  [26] . 
Clinical remission was defined as a continued need for cortico-
steroid replacement for  1 6 months after TS. Biochemical remis-
sion was defined as suppression of serum cortisol  ! 50 nmol/l af-
ter 1 mg overnight dexamethasone and a normal UFC excretion 
(reference  ! 850 nmol/24 h). All patients in remission after sur-
gery (both clinical and biochemical remission) had resolution of 
symptoms of CD (weight loss, improvement of glucose tolerance, 
hypertension and emotional lability). Three groups of outcome 
were identified: sustained remission, early failure (persistent CD), 
and late relapse (recurrence of disease after initial remission). 
During follow-up all patients were re-evaluated initially at 12 
weeks after surgery, followed by 6-monthly intervals in the first 2 
years after surgery and at least annually thereafter. Endocrine 
evaluation consisted of measurement of serum cortisol after 1 mg 
overnight dexamethasone and 24 h UFC excretion along with as-
sessment of anterior pituitary hormone function. Hypopituita-
rism was defined as the presence of hypothyroidism, hypogonad-
ism, growth hormone deficiency or permanent diabetes insipi-
dus. Patients were considered to be growth hormone-deficient if 
serum insulin-like growth factor-1 levels were below the normal 
range at two different intervals or when an impaired response was 
seen during growth hormone stimulation tests.  Eight patients 
died during follow-up. Causes of death were cardiovascular events 
and stroke (4 patients), colorectal cancer (1 patient), cervical can-
cer (1 patient) and unknown (2 patients). Six patients were lost to 
follow-up in the study period. None of the patients who died or 
who were lost to follow-up during the study period suffered from 
active CD ( table 2 ).
 Laboratory Assays 
 Serum cortisol and 24-hour UFC excretion were measured us-
ing a chemiluminescence-based immunoassay (Immulite 2000, 
Siemens, Los Angeles Calif., USA; inter- and intra-assay coeffi-
cients of variation, respectively below 15 and 7%). Urines were 
analyzed without prior solvent extraction.
Table 2. Clinical characteristics of patients who died (n = 8) and who were lost to follow-up (n = 6)
Pat.
No.
Follow-
up
status
Cause of death/
reason lost to FU
Age when lost
to FU/at time
of death, years
Duration of
follow-up
months
Outcome of initial
surgery
Second-line therapy Active CD 
when lost
to FU/death
1 died colorectal cancer 74 70 sustained remission no no
2 died stroke 71 114 sustained remission no no
3 died myocardial infarction 54 37 sustained remission no no
4 died cervical cancer 39 131 sustained remission no no
5 died myocardial infarction 83 103 early failure RT no
6 died unknown 62 48 early failure RT, Bi-ad no
7 died myocardial infarction 40 6 early failure repeat TS, RT, Bi-ad no
8 died cervical cancer 62 50 late relapse repeat TS, RT, Bi-ad no
9 lost myocardial infarction 32 19 sustained remission no no
10 lost unknown 39 72 sustained remission no no
11 lost myocardial infarction 57 86 sustained remission no no
12 lost unknown 35 94 early failure RT, Bi-ad no
13 lost unknown 50 138 early failure RT no
14 lost moved elsewhere 35 92 late relapse RT no
FU = Follow-up; CD = Cushing’s disease; TS = transsphenoidal surgery; RT = radiotherapy; Bi-ad = bilateral adrenalectomy.
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 Plasma ACTH (reference 0–11 pmol/l) was measured using a 
chemiluminescent enzyme immunometric assay (Immulite 2000, 
Siemens, inter- and intra-assay coefficients of variation, respec-
tively below 6.5 and 5.5%). Serum 11-deoxycortisol was measured 
by RIA after extraction (antiserum from Radioassay Systems 
Labs, Carson, USA; inter- and intra-assay coefficients of varia-
tion, respectively below 13 and 12%).
 Statistical Analysis 
 Descriptive statistics were calculated for continuous variables. 
Sensitivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV) were calculated for each test using
2  ! 2 tables (patients in sustained remission were compared with 
patients with early failure of surgery). Relapsing patients were not 
considered. PPV was defined as the likelihood that a subject with 
a positive test had persistent CD after pituitary surgery (treatment 
failure). NPV was defined as the likelihood that a subject with a 
negative test would remain in remission after surgery. Cutoff lev-
els were increased stepwise to determine the optimal combination 
of PPV and NPV. Statistical analysis and graphing were per-
formed using GraphPad Prism version 3.0 (GraphPad Software, 
San Diego, Calif., USA) and MedCalc version 9.6.3 (MedCalc 
Software, Mariakerke, Belgium).
 Results 
 Patient characteristics and test results are shown in 
 table 1 . During the study period, 51 patients (65%) 
achieved immediate postoperative remission. CD re-
curred in 20% of patients after initial successful pituitary 
surgery ( fig. 1 ). The probability of relapse-free survival of 
patients in immediate remission after pituitary surgery 
was 92% at 12 months, 88% at 24 months, 86% at 36 
months and 83% at 84 months ( fig. 2 ). Median time to 
relapse was 16.5 months (range 7–121). Failure to remove 
the adenoma completely, resulting in persistent CD, oc-
curred in 28 patients (35%). These patients received sec-
ond-line therapy, including repeat pituitary surgery, frac-
tionated stereotactic radiotherapy and/or bilateral adre-
nalectomy.
 Macroadenomas accounted for 43% in the early failure 
group. Moreover, in 21% of early failures no adenoma 
could be identified on preoperative MRI. In patients suc-
cessfully operated, the percentage of macroadenomas 
was only 17%.
 Overall, 22 patients (28%) were left with partial or 
complete hypopituitarism. Ten patients in sustained re-
mission (24%) developed partial or complete hypopitu-
itarism after TS compared with 9 of those with surgical 
failure (32%). Deficiency of one or more pituitary hor-
mones was found in 30% of late relapses (3 patients). The 
thyrotropic axis was most frequently affected (17 pa-
tients), followed by gonadotropic (13 patients) and so-
matotropic (7 patients) axes. Permanent diabetes insipi-
dus occurred in 2 patients.
 Morning Serum Cortisol 
 Early postoperative morning serum cortisol levels 
were obtained in 78 patients ( fig. 3 ). Morning serum cor-
tisol levels  ! 200 nmol/l were seen in 33 of 40 patients in 
sustained remission (83%). Seven patients in sustained re-
mission recorded postoperative morning serum cortisol 
79 patients
51 initial remission (65%)
41 sustained
remission
10 late relapse
28 early failures (35%)
 Fig. 1. Clinical outcome of TS for CD in the Erasmus Medical 
Centre Rotterdam, The Netherlands (1991–2006). 
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 Fig. 2. Kaplan-Meier curve showing relapse-free survival of pa-
tients in initial remission after pituitary surgery for CD in the 
Erasmus Medical Centre Rotterdam, The Netherlands (1991–
2006). 
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levels in excess of 200 nmol/l (median follow-up 66 
months, range 40–154). Six of these 7 patients had re-
ceived pretreatment with ketoconazole. Cortisol levels 
 1 200 nmol/l were seen in 96% of patients with persistent 
CD (early failures). All patients with recurrent CD, except 
one, had morning serum cortisol concentrations of at 
least 50 nmol/l. In our series, a threshold value of 200 
nmol/l for morning serum cortisol obtained within 2 
weeks after pituitary surgery resulted in a PPV of 79% for 
immediate postoperative failure (NPV 97%).
0
Sustained
remission
(n = 40)
Early
failure
(n = 28)
Late
relapse
(n = 10)
Outcome
200 nmol/l
Cortisol >200 nmol/l
PPV = 79%
NPV = 97%
Sensitivity = 96%
Specificity = 83%
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 Fig. 3. Morning serum cortisol levels of 78 
patients after pituitary surgery for CD. A 
cutoff level of 200 nmol/l predicts early 
failure of surgery in 79% of patients. All 
relapses, except one, recorded early post-
operative morning serum cortisol levels 
 1 50 nmol/l. 
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Sustained
remission
(n = 32)
Early
failure
(n = 18)
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(n = 3)
Outcome
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Peak cortisol>600 nmol/l
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 Fig. 4. Peak serum cortisol concentrations 
of 53 patients in response to human CRH 
administration after TS for CD. A thresh-
old value of 600 nmol/l results in a PPV of 
78% for immediate surgical failure (NPV 
100%). 
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 CRH Stimulation Test 
 The responsiveness to CRH (human CRH 100   g i.v.) 
was  studied   in   53   patients   postoperatively.   Results   of  
the CRH stimulation test are shown in  figure 4 . All pa-
tients with persistent hypercortisolism (18 early failures) 
showed absolute peak cortisol levels  1 600 nmol/l after 
CRH administration. Only 5 of 32 patients in sustained 
remission also had cortisol values in excess of 600
nmol/l (median follow-up 55 months, range 40–70). All 5 
had received ketoconazole treatment prior to pituitary 
surgery and also recorded morning serum cortisol con-
centrations  1 200 nmol/l in the early postoperative phase. 
All patients with recurrent CD (n = 3) recorded peak se-
rum cortisol levels  1 485 nmol/l after CRH administra-
tion. In the present study, absolute peak serum cortisol 
levels  1 600 nmol/l after CRH predicted immediate surgi-
cal failure in 78% of cases (NPV 100%). Measurement of 
plasma ACTH and calculation of the incremental chang-
es in cortisol and ACTH did not improve discrimination 
between groups (data not shown).
 Metyrapone Stimulation Test 
 Metyrapone test was performed in 72 subjects. The 
results of the postoperative metyrapone test are shown in 
 figure 5 . 89% of patients in sustained remission (33 out of 
37) recorded 11-deoxycortisol levels  ! 345 nmol/l after 
6  ! 750 mg metyrapone. However, metyrapone-stimu-
lated 11-deoxycortisol concentrations of  1 345 nmol/l 
were seen in 4 patients in sustained remission (median 
follow-up 77 months, range 55–114); 3 of these 4 patients 
had been treated with ketoconazole before TS. 93% of pa-
tients with persistent CD after surgery (n = 25) noted 11-
deoxycortisol levels  1 345 nmol/l. Although 11-deoxycor-
tisol levels ranged from 12 to 470 nmol/l in patients with 
recurrent disease after apparent remission, the majority 
of patients (75%) had 11-deoxycortisol concentrations of 
 ! 345 nmol/l. In the present study, serum 11-deoxycorti-
sol levels of  1 345 nmol/l in response to metyrapone pre-
dicted early failure of TS in 86% of cases (NPV 94%).
 Combined Assessment 
 In 49 patients (29 patients in sustained remission, 18 
early failures, and 2 relapses) all three postoperative tests 
were performed (morning serum cortisol, CRH test, and 
metyrapone test). Of the 29 patients in sustained remis-
sion who underwent all three tests, 12 recorded postop-
erative morning serum cortisol levels  ! 50 nmol/l. All of 
these 12 patients with ‘undetectable’ postoperative corti-
sol concentrations showed relative unresponsiveness to 
CRH stimulation, with peak cortisol concentrations 
ranging from 28 to 80 nmol/l. Furthermore, all 12 also 
showed an impaired response to metyrapone administra-
tion with serum 11-deoxycortisol levels varying from 10 
to 78 nmol/l.
0
Sustained
remission
(n = 37)
Early
failure
(n = 27)
Late
relapse
(n = 8)
Outcome
345 nmol/l
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Specificity = 89%
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 Fig. 5. Early postoperative 11-deoxycorti-
sol levels after metyrapone (6  ! 750 mg) 
in 72 patients with CD. The metyrapone 
test has a PPV of 86% to detect immediate 
failure of pituitary surgery when a cutoff 
value of 345 nmol/l is used (NPV 94%). 
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 Only 1 patient in the early failure group measured a 
postoperative morning serum cortisol level (152 nmol/l) 
below the cutoff value of 200 nmol/l. She also recorded 
an insufficient response to metyrapone administration 
(11-deoxycortisol 208 nmol/l). In the CRH test however, 
she showed a significant cortisol response (677 nmol/l) 
exceeding the cutoff point of 600 nmol/l.
 Two patients with recurrent CD underwent all three 
postoperative tests. One patient had a suppressed morn-
ing serum cortisol value of 51 nmol/l and reached an ab-
solute serum cortisol peak concentration of 485 nmol/l in 
the CRH test. Response in the postoperative metyrapone 
test was also subnormal (11-deoxycortisol 200 nmol/l). 
The second patient with recurrent disease had a postop-
erative morning cortisol value of 386 nmol/l and also 
showed a substantial response in both CRH test (peak 
cortisol 568 nmol/l) and metyrapone test (11-deoxycor-
tisol 470 nmol/l).
 Discussion 
 The ultimate goal of a selective transsphenoidal ade-
nomectomy in CD is a complete removal of the cortico-
tropic adenoma without causing loss of normal pituitary 
functions. After TS, however, a substantial number of pa-
tients have persistent CD or develop recurrent tumors 
during follow-up. We examined early and late outcome of 
pituitary surgery as well as predictive values of early post-
operative tests in a large cohort of patients with CD dur-
ing a median follow-up period of 84 months.
 Early and Late Outcome of Pituitary Surgery 
 The immediate postoperative and overall remission 
rates in the current paper fall at the lower end of the re-
ported outcome data from other centers  [4–12, 27] . This 
may be explained by a number of reasons. Firstly, vari-
ability in remission rates can be attributed to the different 
criteria used to define postoperative remission. We used 
adequate suppression of serum cortisol after 1 mg over-
night dexamethasone in combination with a normal UFC 
excretion as definition of biochemical remission. Thus, 
remission or failure were defined independently of the 
tests that were examined. Secondly, there is considerable 
difference in duration of follow-up between published 
studies. Prolonged follow-up leads to lower cure rates, as 
the incidence of relapse increases with time. In our study, 
recurrent CD occurred  1 10 years after initially successful 
pituitary surgery in 1 patient, indicating that lifelong fol-
low-up of patients with CD is mandatory. Thirdly, we re-
port the surgical outcome of a heterogeneous group of 
adenomas, i.e. both micro- and macroadenomas, where-
as some clinical series only report results of TS in micro-
adenomas  [4, 27] . Remission rates are lower in patients 
with macroadenomas  [1, 28, 29] . This finding is con-
firmed in the present survey in which 43% of patients 
with surgical failure had a corticotropic macroadenoma. 
Finally, extensive surgical exploration, as performed in 
some centers, may result in higher cure rates. However, 
this is at the expense of postoperative pituitary function 
loss. Hypopituitarism after pituitary surgery is associat-
ed with an impaired health-related quality of life  [30, 31] . 
The trend towards more conservative surgery in our cen-
ter, aimed at preserving pituitary functions, has resulted 
in a relatively favorable hypopituitarism rate. Overall, we 
found 28% of patients to have postoperative hormonal 
disturbances compared to 26–52% reported elsewhere 
 [11, 15, 16, 32] .
 Prediction of Surgical Outcome 
 Which biochemical parameters most reliably predict 
the long-term outcome after TS is still a matter of debate. 
Immediate postoperative recognition of patients with 
persistent CD or at risk for relapse would allow addition-
al therapeutic measures to be undertaken at an early 
stage. When judged by long-term outcome, a postopera-
tive serum cortisol level  ! 50 nmol/l has been regarded as 
the best predictor for long-term remission and is associ-
ated with a 10-year recurrence rate of approximately 10% 
 [1, 6, 12–16, 33] . This finding was confirmed in the pres-
ent study in which remissions were associated with sup-
pressed morning serum cortisol levels. 89% of relapses 
recorded  postoperative morning cortisol levels  1 50 
nmol/l. Thus, persistently detectable serum cortisol con-
centrations in the early postoperative phase can be in-
dicative of incomplete resection of the corticotropic ad-
enoma and an increased risk of recurrence. It must be 
emphasized, however, that detectable morning cortisol 
levels ( 1 50 nmol/l) are not necessarily followed by recur-
rence of CD, which might in part be explained by preop-
erative treatment with ketoconazole (see below). More-
over, our study confirms that relapse can occur even in 
the presence of postoperative hypocortisolism.
 The CRH test is a widely used non-invasive test to dis-
criminate CD from Cushing’s syndrome due to ectopic 
ACTH secretion  [34–36] . Both ovine and human CRH 
have been used in clinical studies, although there is no 
consensus on the response criteria. In the current survey, 
we studied the results of the early postoperative human 
CRH test. Compared to peak ACTH level and incremen-
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tal changes in cortisol and ACTH concentration, the ab-
solute peak cortisol concentration after CRH stimulation 
gave the best diagnostic accuracy in predicting outcome 
of pituitary surgery. All failures and recurrences showed 
a significant rise in serum cortisol during the time course 
of the test using a cutoff value of 600 nmol/l. In accor-
dance with previously reported literature, we found that 
suppressed responses to CRH during the early postop-
erative period are indicative of long-term remission of 
CD  [6, 7, 18–21] . However, similar to morning cortisol 
levels, a subset of patients who were in sustained remis-
sion exhibited post-CRH cortisol levels  1 600 nmol/l 
which may in part be related to ketoconazole treatment 
before TS (see below).
 Metyrapone blocks cortisol synthesis by competitively 
inhibiting 11  -hydroxylation in the adrenal cortex. This 
stimulates ACTH secretion, leading to increased produc-
tion of cortisol precursors such as 11-deoxycortisol. 
Therefore, the metyrapone test can be used in establish-
ing the diagnosis of secondary adrenal insufficiency  [37–
39] . We studied the results of the metyrapone test carried 
out in patients after pituitary surgery for CD in order
to establish its usefulness in the assessment of surgical 
outcome. Postoperatively, the majority of patients with 
persisting CD had markedly increased levels of metyra-
pone-stimulated 11-deoxycortisol compared to patients 
in sustained remission. Previously, van Aken et al.  [17] 
reported in a small number of patients 100% sensitivity 
for the early postoperative metyrapone test in detecting 
patients at risk for recurrent CD when an 11-deoxycorti-
sol cutoff value of 150 nmol/l was used. However, in the 
present study, we found great variability of 11-deoxycor-
tisol levels in patients with recurrent CD, ranging from 
12 to 470 nmol/l. Therefore, according to the current 
data, the usefulness of the metyrapone test in the early 
prediction of relapse is limited.
 Combining the results of all three postoperative tests 
(serum cortisol, CRH test, and metyrapone test) we found 
that patients in sustained remission with suppressed 
postoperative morning serum cortisol concentrations 
also showed a relative concordant unresponsiveness to 
CRH stimulation and metyrapone administration. Com-
parison of PPVs and NPVs of the investigated tests shows 
that the additional value of CRH and metyrapone testing 
to measurement of morning serum cortisol levels is 
 limited.
 Pretreatment with Cortisol-Lowering Drugs 
 CD is associated with diabetes, hypertension, poor 
wound healing, hemorrhagic diathesis and increased tis-
sue fragility. In order to control hypercortisolemia and 
minimize perioperative risks, medical therapy with keto-
conazole prior to surgery is used in several centers. In 
previous studies on postoperative biochemical testing in 
CD, results have not been interpreted in relation to even-
tual preoperative treatment with cortisol-lowering drugs 
 [7, 12, 32] . In the present study, 75% of patients were pre-
treated with ketoconazole. Interestingly, 6 of the 7 pa-
tients in sustained remission with postoperative serum 
cortisol levels  1 200 nmol/l received presurgical treat-
ment with ketoconazole. It is possible that these patients, 
after an apparent remission, will ultimately develop re-
currence of CD. However, the median follow-up of these 
patients was 5.5 years, making recurrent CD in future 
still possible but less likely. However, an alternative expla-
nation is that the treatment with ketoconazole prior to 
surgery could have resulted in higher postoperative basal 
and CRH-stimulated cortisol levels in these patients due 
to early recovery of suppressed non-tumor corticotropic 
cells and subsequent restoration of pituitary-adrenal 
function. Future studies should investigate the possible 
relationship between preoperative achievement and du-
ration of normocortisolism after ketoconazole pretreat-
ment and the postoperative recovery of the pituitary-ad-
renal axis.
 Conclusions 
 In our study we identified undetectable morning se-
rum cortisol concentrations and an impaired responsive-
ness to CRH and metyrapone stimulation in the early 
postoperative period as biochemical predictors of long-
term remission. Recurrent CD seems to be associated 
with higher morning serum cortisol levels and an unsup-
pressed CRH-stimulated cortisol response. However, 
there is considerable overlap between patients who do 
and those who do not relapse. In our series we could not 
clearly identify the benefits of performing additional 
CRH and/or metyrapone tests in the postoperative as-
sessment of patients with CD. In addition, pretreatment 
with cortisol-lowering drugs may influence the results of 
different postoperative biochemical tests. Future studies 
are necessary to determine the effects of preoperative ke-
toconazole treatment on the recovery of the hypothalam-
ic-pituitary-adrenal axis in patients who are in remission 
after pituitary surgery. 
 Biochemical Predictors of Outcome of 
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